|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Sunday
NEW DRUG IN THE PIPELINE FOR MS: Daclizumab for the treatment of MS:
"It's easy to understand the $800 million alliance forged between PDL Biopharma and Biogen Idec in August. The deal answers Biogen's pipeline needs and provides PDL a kindred biotech with experience in MS and cancer...The deal calls for PDL and Biogen to jointly develop, manufacture and sell three antibody products in mid-stage clinical trials. This includes PDL's drug Daclizumab for the treatment of MS......" |